Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype

• Published in: Japanese journal of clinical oncology 2014-11, Vol.44 (11), p.1025-1031
• Main Authors: Kuba, Sayaka, Ishida, Mayumi, Nakamura, Yoshiaki, Yamanouchi, Kosho, Minami, Shigeki, Taguchi, Kenichi, Eguchi, Susumu, Ohno, Shinji
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biomarkers, Tumor - analysis; Brain Neoplasms - secondary; Brain Neoplasms - therapy; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Female; Humans; Kaplan-Meier Estimate; Medical Records; Middle Aged; Predictive Value of Tests; Prognosis; Radiosurgery; Receptor, ErbB-2 - analysis; Receptors, Estrogen - analysis; Receptors, Progesterone - analysis; Retrospective Studies; Triple Negative Breast Neoplasms - pathology; Triple Negative Breast Neoplasms - therapy
• ISSN: 0368-2811; 1465-3621
• DOI: 10.1093/jjco/hyu126

How breast cancer subtypes should affect treatment decisions for breast cancer patients with brain metastases is unclear. We analyzed local brain metastases treatments and their outcomes according to subtype in patients with breast cancer and brain metastases. We reviewed records and database information for women treated at the National Kyushu Cancer Center between 2001 and 2010. Patients were divided into three breast cancer subtype groups: Luminal (estrogen receptor positive and/or progesterone receptor positive, but human epidermal growth factor receptor 2 negative); human epidermal growth factor receptor 2 positive and triple negative (estrogen receptor negative, progesterone receptor negative and human epidermal growth factor receptor 2 negative). Of 524 advanced breast cancer patients, we reviewed 65 (12%) with brain metastases and records showing estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status, as well as outcome data; there were 26 (40%) Luminal, 26 (40%) had human epidermal growth factor receptor 2 and 13 (20%) had triple negative subtypes. There was no statistical difference in the number of brain metastases among subtypes; however, rates of stereotactic radiosurgery or surgery for brain metastases differed significantly by subtype (human epidermal growth factor receptor 2: 81%, Luminal: 42% and triple negative: 47%; P = 0.03). Patients having the human epidermal growth factor receptor 2 subtype, a performance status of ≤1 and ≤4 brain metastases, who underwent systemic therapy after brain metastases and underwent stereotactic radiosurgery or surgery, were predicted to have longer overall survival after brain metastases. Multivariate analysis demonstrated that not having systemic therapy and not having the human epidermal growth factor receptor 2 subtype were independent factors associated with an increased risk of death (hazard ratio 2.4, 95% confidence interval 1.01-5.6; P = 0.05 and hazard ratio 2.9, 95% confidence interval 1.5-5.8; P = 0.003, respectively). Our study showed that local brain treatments and prognosis differed by subtype in breast cancer patients with brain metastases.